Industry Blogs and Articles

Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation

Pulse Biosciences reported long‑term results from its first‑in‑human nPulse Vybrance study, showing an average 74% reduction in benign thyroid nodule volume after 15‑22 months. The data, presented at the 2026 North American Society for Interventional Thyroidology meeting, revealed no nodule regrowth, no serious adverse events, and high patient satisfaction. The findings highlight the durability of nanosecond pulsed field ablation (nsPFA) as a non‑thermal alternative to conventional thermal ablation techniques. The study followed 21 patients through extended monitoring to confirm sustained outcomes.